Composite probiotics for improving inflammatory bowel disease and application thereof

By using a complex probiotic composition of Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae, the treatment of ulcerative colitis lacking low side effects in the prior art was solved, significantly improving the intestinal health and production benefits of animals, and achieving the achievement of Reduction of inflammation and oxidative damage and regulation of intestinal flora.

CN118995512APending Publication Date: 2024-11-22HUAZHONG AGRI UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411224488.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art lacks effective drugs with low side effects to improve inflammatory bowel disease, especially ulcerative colitis, affecting the health and production benefits of animals.

Method used

Using a complex probiotic composition, including Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae, a combination of 1:1:1 was screened through stress resistance tests, antibacterial tests and enzyme production tests, for improvement Intestinal function and flora structure in mouse ulcerative colitis model.

Benefits of technology

Complex probiotics significantly improved the symptoms of ulcerative colitis in mice, restored intestinal barrier function, reduced inflammation and oxidative damage, regulated intestinal flora diversity, improved antioxidant capacity, and provided a potential treatment and feed additives to improve animal health and production efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995512A_ABST
    Figure CN118995512A_ABST
Patent Text Reader

Abstract

The invention discloses compound probiotics for improving inflammatory bowel disease and application thereof, and belongs to the technical field of biological medicine. The compound probiotics for improving the inflammatory bowel disease comprise bacillus licheniformis, lactobacillus plantarum and saccharomyces cerevisiae, the dosage ratio of the bacillus licheniformis to the lactobacillus plantarum to the saccharomyces cerevisiae is (1-3): (1-3): (1-3); the compound probiotics disclosed by the invention have excellent performance in the aspects of stress resistance, bacteriostasis, enzyme production and the like; the conditions of weight loss, disease activity index increase, intestinal barrier damage, intestinal flora imbalance and the like of mice caused by ulcerative colitis can be improved; and inflammation and oxidative damage of mouse ulcerative colitis can be relieved. The compound probiotics disclosed by the invention can be applied to preparation of medicines for treating inflammatory bowel diseases; the feed additive can also be applied to preparation of feed additives for improving animal intestinal health, production benefits can be remarkably improved, intestinal injury can be relieved, and damage to animal intestinal barriers is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a composite probiotic for improving inflammatory bowel disease and an application thereof. Background Art

[0002] The intestine is the main organ for animal digestion and absorption, and also performs the related functions of immune organs. The growth and health of animals are closely related to the integrity of intestinal function. Because the intestine performs the function of food digestion and absorption, its mucosal layer can come into contact with different types of antigens, thereby affecting the development of the body's immune system. The intestinal mucosal barrier is an important line of defense against pathogen invasion. In animal breeding, there are many factors that cause the homeostasis of the animal's intestine to be destroyed, the mucosal barrier function to decline, and then lead to adverse reactions in the animal's systemic body. Therefore, maintaining the homeostasis of the animal's intestine has a positive effect on improving the growth performance and health of the animal.

[0003] Probiotics are a type of microorganism that can improve the health of the host. They can participate in the digestion, absorption and immune function of animals in the intestines. In previous studies, probiotics have shown improvement functions for diseases such as ulcerative colitis, but they are mostly focused on the application of a single strain of bacteria, and the combined application of multiple strains of probiotics is less common. Different probiotics may improve the health of the host through different mechanisms. There are many types of probiotics, and different types of probiotics have their own advantages and disadvantages in application. The probiotic properties of different probiotics are often different, which leads to differences in their mechanisms of action in the host.

[0004] The protective effect of probiotics on digestive health has always been a hot topic of research. Probiotics can be seen in related studies of diarrhea, constipation, inflammatory bowel disease, intestinal cancer and other diseases. There are many causes of diarrhea. Probiotics with different characteristics can improve diarrhea caused by different reasons in a targeted manner. For example, Saccharomyces boulardii can restore the intestinal flora destroyed by antibiotics and has a good protective effect on antibiotic-associated diarrhea; Lactobacillus rhamnosus can antagonize common intestinal pathogens and prevent traveler's diarrhea. Some lactic acid bacteria can restore intestinal motility and improve constipation. Inflammatory bowel disease is often accompanied by an imbalance of the intestinal microbiota. The imbalance of the microbiota may enhance the host's inflammatory response and lead to a vicious cycle. Supplementing with probiotics is one of the effective means to adjust the intestinal flora. It may also improve symptoms through other mechanisms such as enhancing the intestinal barrier function and regulating immune function.

[0005] On the other hand, probiotics can improve pain caused by intestinal diseases. For example, Lactobacillus plantarum PS128 can reduce the level of 5-hydroxytryptophan and inhibit its visceral allergic pain induced during colorectal dilatation; Lactobacillus plantarum MTCC 2621 can upregulate the level of IL-10 to improve inflammatory pain caused by Staphylococcus aureus infected wounds.

[0006] Probiotics can also reproduce through special metabolites or by antagonizing the invasion of pathogens. The intestinal microbiome is considered to be an organ with unique metabolic capabilities. Different types of probiotics produce different metabolites and have different mechanisms of action. In previous studies, it was found that a class of probiotics that can produce short-chain fatty acids such as acetic acid and butyric acid can change the acid-base environment in the host intestine through short-chain fatty acids, thereby inhibiting the proliferation of pathogenic microorganisms. Defensins are also one of the special metabolites of probiotics. Their antibacterial activity can play a good protective role in the host intestine. Brevibacillus can produce an antimicrobial peptide called brevicaulin, so it has been commercially applied to a certain extent. Many food-borne lactic acid bacteria can produce bacteriocins, which are special metabolites with antibacterial properties and have good inhibitory effects on food-borne pathogens such as Staphylococcus aureus and Escherichia coli. In addition, probiotics can also produce special metabolites such as lactic acid, acetate, and lysozyme. Their antibacterial properties can resist the invasion of pathogens and protect the intestinal health of the host.

[0007] Ulcerative colitis is an idiopathic inflammatory bowel disease of the colonic mucosa. Blood in the stool and diarrhea are characteristic symptoms of ulcerative colitis. The lesions start from the rectum and spread to the colon and even cover the entire colon. Autopsy revealed that the colon often had edema, bleeding, shortened length and other lesions. Histologically, ulcerative colitis is often manifested as atrophy, deformation and upward migration of crypts, epithelial cell damage, goblet cell reduction or granulomas. The etiology of ulcerative colitis is complex and is related to genetic genes, individual immune system status, intestinal microecology, and environmental factors. The stability of the intestinal microecology is closely related to the development of ulcerative colitis. In previous studies, ulcerative colitis usually causes a significant change in the intestinal microbial composition of animals, and this change in turn aggravates the symptoms of colitis, forming a vicious circle. Microorganisms in the intestine act on the intestinal mucosa, causing low-level inflammation, thereby regulating mucosal immunity to improve it, and playing a certain role in monitoring and clearing pathogens in the intestine. At the same time, intestinal flora adheres to the surface of intestinal epithelial cells to form a biological barrier. Therefore, when the balance of the intestinal microecology is broken, the intestinal barrier and mucosal immune function will be damaged to a certain extent, leading to disease. More and more studies have shown that oxidative stress is also closely related to inflammation. There are also studies that have shown that oxidative stress plays an important role in the occurrence of ulcerative colitis. Immune disorders and inflammation will also increase the level of reactive oxygen in the body, causing the balance of redox to be broken. The impact of intestinal microorganisms on host health has received widespread attention. On the one hand, many studies have pointed out that the intestinal microbiome can indicate the health status of the host and reflect the progress of intestinal diseases. On the other hand, the intestinal microbiome can affect the health of the host by regulating the host's digestion and absorption function, immune function, etc.

[0008] It can be seen that the development of compound probiotics that can improve inflammatory bowel disease is particularly important for the development of drugs for inflammatory bowel disease. Summary of the invention

[0009] The present invention provides a composite probiotic for improving inflammatory bowel disease and its application, aiming to solve the problem of the lack of effective drugs for inflammatory bowel disease with low side effects. The present invention constructs a mouse ulcerative colitis model, analyzes the effects of the composite probiotic on the antioxidant function, inflammatory response and intestinal flora of the intestine in the mouse colitis model, and thus confirms the protective effect of the composite probiotic on intestinal function.

[0010] The technical solution of the present invention is achieved in this way:

[0011] A composite probiotic for improving inflammatory bowel disease comprises bacillus licheniformis, lactobacillus plantarum and saccharomyces cerevisiae; the dosage ratio of the bacillus licheniformis, lactobacillus plantarum and saccharomyces cerevisiae is 1-3:1-3:1-3.

[0012] Further preferably, in the composite probiotics, the usage ratio of Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae is 1:1:1.

[0013] Further preferably, in the composite probiotics, the amounts of Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae are 1-3×10 9 CFU, 1-3×10 9 CFU, 1-3×10 9 CFU.

[0014] More preferably, in the composite probiotics, the amounts of Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae are 1×10 9 CFU, 1×10 9 CFU, 1×10 9 CFU.

[0015] Further preferably, the Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae are all purchased from Shandong Weilan Biotechnology Co., Ltd., the product code of the Bacillus licheniformis is U-1000, the product code of the Lactobacillus plantarum is zw-1000, and the product code of the Saccharomyces cerevisiae is NJJM-200.

[0016] The present invention conducts stress resistance test, antibacterial test, enzyme production test and mutual inhibition test through the probiotic components in the composite probiotics. The results show that the comprehensive survival rate of Saccharomyces cerevisiae in acid resistance, bile salt resistance and high temperature resistance tests is the highest, reaching 58.85%, 69.88% and 82.51% respectively; Lactobacillus plantarum has the largest diameter of the antibacterial circle produced in the antibacterial test; Bacillus licheniformis has the largest ratio of the transparent circle diameter to the colony diameter in the enzyme production test; and the three probiotics in the composite probiotics have no obvious mutual inhibition. Comprehensive analysis of the above in vitro test results shows that Saccharomyces cerevisiae, Lactobacillus plantarum and Bacillus licheniformis have good probiotic properties, and there is no mutual inhibition between the three probiotics, and they have the potential to be a composite probiotic that can improve ulcerative colitis.

[0017] In order to explore the protective effect of compound probiotics on ulcerative colitis in mice, a control group, a DSS-treated group, a compound probiotics group, and a compound probiotics + DSS-treated group were used. 9 After intragastric administration of 1000 CFU (100 μg / mL) of DSS for 14 days, mice were given drinking water containing 3% DSS for 7 days. The weight and food intake of mice were recorded, and the colon tissue and its contents were collected. The results showed that the weight, food intake and colon length of mice in the DSS-treated group decreased; the disease activity index of mice (including weight loss, fecal viscosity and rectal bleeding) increased significantly; the related organ indexes of spleen, kidney and liver increased; the morphological structure of colon tissue was destroyed, the mucosal layer was degenerated and necrotic, and the crypts were atrophied; the expression levels of tight junction proteins Claudin-1 and ZO-1 decreased. The treatment with compound probiotics can alleviate the decrease in weight, food intake and colon length of mice, reduce the disease activity index and related organ indexes, protect the normal structure of colon tissue, and restore the expression level of tight junction proteins. These results show that compound probiotics can improve ulcerative colitis in mice.

[0018] In the present invention, by detecting mouse serum and colon tissue, it was found that the compound probiotics treatment can reverse the expression of inflammatory cytokines, inhibit the activation of the NF-κB signaling pathway, restore the level of oxidation markers, and increase the protein expression level of Nrf2 and HO-1. The above results show that the compound probiotics can reduce the inflammation level of mice with ulcerative colitis, restore the antioxidant capacity of mice, and reduce intestinal oxidative damage caused by ulcerative colitis.

[0019] In addition, the present invention detected the effects of composite probiotics and DSS-induced ulcerative colitis in mice on intestinal flora; the colon contents of mice were collected for flora sequencing. The results showed that after DSS treatment, the Alpha diversity and Beta diversity of the intestinal flora of mice changed significantly, indicating that the diversity of the intestinal flora of mice decreased. At the same time, the composition structure of the flora changed significantly. Analysis of the flora composition found that the abundance of unclassified_Muribaculaceae, Ileibacterium, and Prevotellaceae_UCG_001 decreased after DSS treatment, and the cooperative relationship between the flora weakened. Correlation analysis of the flora and environmental factors found that unclassified_Muribaculaceae, Ileibacterium, and Prevotellaceae_UCG_001 were positively correlated with T-SOD, GSH levels, and the expression levels of Nrf2, IκBα, and IL-10, and negatively correlated with LDH, MDA, MPO levels, and the expression levels of TNF-α, IL-1β, IL-6, and p65. However, Clostridium_sensu_stricto_1, Escherichia_Shigella, and Parasutterella, which were enriched after DSS treatment, showed completely opposite correlations. After treatment with compound probiotics, the diversity of the microbiota was restored, the interaction between the microbiota was improved, and the changes in the composition of the microbiota were reversed. The above results indicate that compound probiotics can improve colitis in mice by regulating intestinal flora.

[0020] Through the detection of the effect of the above-mentioned composite probiotics on ulcerative colitis in mice, it can be known that the above-mentioned composite probiotics are used in the preparation of drugs for treating inflammatory bowel disease.

[0021] More preferably, the inflammatory bowel disease is ulcerative colitis.

[0022] More preferably, the ulcerative colitis includes ulcerative colitis induced by dextran sulfate sodium (DSS).

[0023] The composite probiotics are used in the preparation of feed additives for improving the intestinal health of animals.

[0024] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:

[0025] The composite probiotics of the present invention have excellent performance in stress resistance, antibacterial and enzyme production, etc.; they can improve the weight loss, increased disease activity index, intestinal barrier damage and intestinal flora imbalance of mice caused by ulcerative colitis; and they can reduce the inflammation and oxidative damage of ulcerative colitis in mice. The composite probiotics of the present invention can be used in the preparation of drugs for treating inflammatory bowel disease, and can also be used in the preparation of feed additives for improving the intestinal health of animals; they can be used in animal husbandry production, and by adding composite probiotics, production efficiency can be improved and intestinal damage can be alleviated, the effects caused by pathogenic microorganism infection, improper feeding and management, etc. can be improved, the intestinal barrier of animals can be reduced, the growth performance of animals can be improved, and serious economic losses caused by induced diseases can be avoided. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The colony morphology of the probiotics in the examples is shown in Figure 1, wherein A: Bacillus subtilis; B: Bacillus licheniformis; C: Lactobacillus plantarum; D: Enterococcus faecalis; and E: Saccharomyces cerevisiae.

[0027] Figure 2 The Gram staining results of the probiotics in the examples are shown in Figure 1, wherein A: Bacillus subtilis; B: Bacillus licheniformis; C: Lactobacillus plantarum; and D: Enterococcus faecalis.

[0028] Figure 3 The results of 16SrRNA and 26SrRNA gene sequence amplification of five probiotics in the example are shown in FIG. 1 , wherein M: DNA Marker; 1: Bacillus subtilis; 2: Bacillus licheniformis; 3: Lactobacillus plantarum; 4: Enterococcus faecalis; and 5: Saccharomyces cerevisiae.

[0029] Figure 4 The graphs are the results of the stress resistance and growth curves of the five probiotics in the examples; A: the tolerance of the probiotics to high temperature; B: the tolerance of the probiotics to acid; C: the tolerance of the probiotics to bile salts; and D: the growth curve of the probiotics.

[0030] Figure 5 The graph is a result of measuring the antibacterial ability of the probiotics in the example against Staphylococcus aureus and Escherichia coli; wherein a is Bacillus subtilis, b is Bacillus licheniformis, c is Lactobacillus plantarum, d is Enterococcus faecalis, e is Saccharomyces cerevisiae, and f is a control.

[0031] Figure 6 1 is a graph showing the results of the protease production capacity determination of the probiotics in the examples; wherein a is Bacillus subtilis, b is Bacillus licheniformis, c is Lactobacillus plantarum, d is Enterococcus faecalis, e is Saccharomyces cerevisiae, and f is a control.

[0032] Figure 7The results of the inhibitory effect determination between probiotics in the examples are shown in Figure 1, where A: the inhibitory effect between Bacillus licheniformis and other probiotics; B: the inhibitory effect between Lactobacillus plantarum and other probiotics; C: the inhibitory effect between Saccharomyces cerevisiae and other probiotics. A is Bacillus subtilis, B is Bacillus licheniformis, C is Lactobacillus plantarum, D is Enterococcus faecalis, and E is Saccharomyces cerevisiae.

[0033] Figure 8 The figure is the effect of the composite probiotics on the body weight, food intake and related organ indexes of colitis mice in the embodiment; wherein AC: mouse body weight, food intake, disease activity index; DF: related organ indexes of mouse spleen, liver and kidney; significant differences are *, r<0.05; **, r<0.01; ***, r<0.001; ns, r>0.05, the same below.

[0034] Fig. 9 The results of the effect of compound probiotics on the length of the colon of colitis mice in the example are shown in Figure 1; A: photos of the mouse colon; B: statistics of the length of the mouse colon. The significant differences are *, r<0.05; **, r<0.01; ***, r<0.001; ns, r>0.05.

[0035] Fig.10 The results of the effects of the composite probiotics on the colon tissue morphology and tight junction protein expression in colitis mice in the examples are shown in Figure 1; A: HE staining of mouse colon; B: Claudin-1 immunohistochemistry; C: ZO-1 immunohistochemistry; DE: mRNA expression levels of Claudin-1 and ZO-1.

[0036] Fig.11 Result diagram of the effect of composite probiotics on intestinal oxidative damage in colitis mice in the example; wherein AF: T-SOD enzyme activity, GSH content, MDA content in mouse serum and colon tissue; G: LDH enzyme activity in mouse serum; HJ: Nrf2, HO-1 protein expression levels.

[0037] Fig.12 The results of the effect of compound probiotics on intestinal inflammation in colitis mice; AD: mRNA expression levels of IL-6, IL-1β, TNF-α, and IL-10; E: serum MPO enzyme activity; FH: p65 and IκBα protein expression levels.

[0038] Fig.13The results of the effect of compound probiotics on the intestinal flora clustering of colitis mice in the embodiment are shown in Figure 1; A: dilution curve; B: Shannon index curve; C: OUT number distribution diagram; D: Venn diagram. C is the Control group, D is the DSS group, P is the Probiotics group, and DP is the DSS+Probiotics group.

[0039] Fig.14 The results of the effect of compound probiotics on the diversity of intestinal flora in colitis mice in the embodiment are shown in the figure; A: ACE index; B: Chao1 index; C: Shannon index; D: Simpson index; E: non-metric multidimensional calibration analysis; F: principal coordinate analysis; G: heat map of distance between samples; H: UPGMA tree column diagram. C is the Control group, D is the DSS group, P is the Probiotics group, and DP is the DSS+Probiotics group.

[0040] Fig.15 The results of the effect of compound probiotics on the intestinal flora composition of colitis mice in the examples (phylum level); A: phylum level species distribution bar graph; B: phylum level ANOVA analysis bar graph. C is the Control group, D is the DSS group, P is the Probiotics group, and DP is the DSS+Probiotics group.

[0041] Fig.16 The results of the effects of the composite probiotics on the intestinal flora of colitis mice in the examples (genus level) are shown; A: genus level species distribution bar graph; B: genus level ANOVA analysis bar graph; C is the Control group, D is the DSS group, P is the Probiotics group, and DP is the DSS+Probiotics group.

[0042] Fig.17 The results of LEfSe analysis in the embodiment are shown in Figure 1; A: LDA value distribution bar graph; B: species evolution branch diagram.

[0043] Among them, C is the Control group, D is the DSS group, P is the Probiotics group, and DP is the DSS+Probiotics group.

[0044] Fig.18 These are the results of the effects of the composite probiotics on the correlation of intestinal flora in colitis mice in the examples; A: correlation network diagram of the Control group; B: correlation network diagram of the DSS group; C: correlation network diagram of the Probiotics group; and D: correlation network diagram of the DSS+Probiotics group.

[0045] Fig.19The results of the effects of the composite probiotics on the correlation between intestinal flora and environmental factors in colitis mice in the examples are shown in the figure; A: a heat map of the correlation between intestinal flora and environmental factors related to antioxidant function; B: a heat map of the correlation between intestinal flora and environmental factors related to inflammation; the significant differences are *, r<0.05; **, r<0.01; ***, r<0.001. DETAILED DESCRIPTION

[0046] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0047] Currently, there is a lack of effective drugs with low side effects for ulcerative colitis. In order to solve the above technical problems, the present invention proposes a screening of composite probiotics and its protective effect on DSS-induced colitis in mice.

[0048] The main experimental materials used in the examples are as follows:

[0049] 1. Microbial materials

[0050] Escherichia coli and Staphylococcus aureus (2 pathogenic bacteria) were kindly donated by the laboratory of Hu Changmin, a teacher at Huazhong Agricultural University. Bacillus subtilis, Bacillus licheniformis, Lactobacillus plantarum, Enterococcus faecalis, and Saccharomyces cerevisiae (5 probiotics) were purchased from Shandong Weilan Biotechnology Co., Ltd. The product code of the Bacillus licheniformis is U-1000, the product code of the Lactobacillus plantarum is zw-1000, and the product code of the Saccharomyces cerevisiae is NJJM-200.

[0051] 2. Animal Materials

[0052] 40 7-week-old SPF-grade healthy male C57BL / 6 mice, standard mouse feed and bedding were purchased from the Experimental Animal Center of Huazhong Agricultural University (Wuhan, Hubei). The animal breeding and use involved in this patent complies with the relevant regulations of the Hubei Provincial Animal Research Center Ethics Committee, and the experimental process complies with the relevant guidelines of the Animal Research Center Committee of Huazhong Agricultural University, is strictly in accordance with the "Guidelines for the Care and Use of Laboratory Animals", and is approved by the Animal Ethics and Use Committee of Huazhong Agricultural University.

[0053] 3. Preparation of main solution

[0054] MRS medium: For liquid culture medium, weigh 20.896 g of MRS broth powder and dissolve it in 400 mL of distilled water. For solid culture medium, weigh 26.48 g of MRS agar powder and dissolve it in 400 mL of distilled water. Sterilize it at 121°C with high-temperature and high-pressure steam for 20 min.

[0055] LB liquid medium: 8 g of tryptone, 4 g of yeast extract, 10 g of sodium chloride, dissolved in 400 mL of distilled water, sterilized by high-temperature and high-pressure steam at 121°C for 20 min. Add 6 g of agar powder to the solid medium.

[0056] YPD liquid medium: 8g of tryptone, 4g of yeast extract, dissolved in 360mL of distilled water; 8g of glucose, dissolved in 40mL of distilled water. Sterilize them separately at 121℃ high temperature and high pressure steam for 20min, mix them after cooling, and store them at room temperature. Add 8g of agar powder to the solid medium.

[0057] TBST: Add 1% Tween-20 to TBS and mix thoroughly.

[0058] 10% sodium dodecyl sulfate SDS solution (10% SDS): weigh 2 g of high-purity SDS and place it in a 100 mL beaker, add about 16 mL of deionized water, heat at 68°C to dissolve, slowly add concentrated hydrochloric acid to adjust the pH to 7.2, dilute to 20 mL, and store at room temperature.

[0059] 10% ammonium persulfate solution (10% APS): weigh 0.1 g of ammonium persulfate and place it in a 1.5 mL centrifuge tube. Add 1 mL of deionized water to fully dissolve it and store it at 4°C.

[0060] Primary antibody diluent: Weigh an appropriate amount of BSA powder and fully dissolve it in TBST to prepare a 5% BSA solution, and store it at 4°C.

[0061] Western Blot blocking solution: Weigh an appropriate amount of skim milk powder and fully dissolve it in TBST to prepare 5% skim milk powder. Prepare and use it at room temperature.

[0062] Example

[0063] 1.1 Cultivation of probiotics

[0064] Take 1g of each of the 5 probiotic freeze-dried powders (Bacillus subtilis, Bacillus licheniformis, Lactobacillus plantarum, Enterococcus faecalis, and Saccharomyces cerevisiae), add them to a 15mL centrifuge tube, add 9mL of sterile saline, and shake until the sample is completely dissolved. Take 0.1mL of the above bacterial suspension in the clean bench, add 0.9mL of sterile water to mix, and dilute to the appropriate concentration in a gradient. Take 0.2mL of the dilution and spread it evenly on the culture dish, place it in a constant temperature incubator at 37℃ and culture for 12-24h. Pick 3-5 colonies of each bacterium and culture them separately to obtain purified single colonies. Pick a single colony in 5mL of liquid culture medium, culture it at 37℃, 220r / min for 12h, mix the obtained bacterial solution with 50% glycerol in a 1:1 ratio, and store it in a -80℃ refrigerator.

[0065] 1.2 Identification of strain 16S rRNA and 26S rRNA

[0066] The primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd. with reference to the universal primers for bacterial 16S rRNA and fungal 26S rRNA. According to the instructions of the PCR reagent, the activated bacterial liquid template was used to configure the reaction system in Table 1:

[0067] Table 1 Identification PCR reaction system

[0068]

[0069] Mix the above reaction system and place the sample in a PCR instrument for reaction. The reaction conditions are: 95℃ pre-denaturation for 3min, 95℃ denaturation for 15s, 45℃ annealing for 15s and 72℃ extension for 25s, 35 cycles, and 72℃ for 5min. The PCR product was sent to Jinkairui Biological Company for sequencing, and the strain type was determined based on the sequence BLAST results. The specific primer sequences are shown in Table 2 below:

[0070] Table 2 Primers used for sequencing

[0071]

[0072] 1.3 Strain growth curve determination

[0073] The activated bacterial solution was adjusted to OD600 value of 1.0, diluted at a ratio of 1:100, and 0.2 mL of the diluted bacterial solution was placed on a 96-well plate of a multifunctional microplate reader, cultured at 37°C, 220 r / min, and the growth of each strain was measured and the data was collected.

[0074] 1.4 Determination of strain stress resistance

[0075] 1. High temperature resistance test: Take the activated bacterial solution and heat treat it at 75℃ for 20s. Dilute all samples to the appropriate multiples, take 0.2mL and apply it on the corresponding plate. Repeat each sample 3 times, observe the growth and count.

[0076] 2. Acid resistance test: Inoculate 10% of the activated bacteria into a medium with pH = 2.5, and culture at 37°C, 220r / min on a shaker for 2h. Dilute all samples to the appropriate multiples, take 0.2mL and spread on a plate, repeat 3 times for each sample, observe the growth and count.

[0077] 3. Bile salt tolerance test: Inoculate 10% of the activated bacteria into a medium containing 0.3% bile salt, and culture at 37°C, 220r / min on a shaker for 2h. Dilute all samples to the appropriate multiples, take 0.2mL and spread on a plate, repeat 3 times for each sample, observe the growth and count.

[0078] 1.5 Determination of antibacterial ability of strains

[0079] 1. Activate 5 strains of probiotics and 2 strains of pathogenic bacteria.

[0080] 2. Preparation of double-layer plates: Add about 25 mL of MRS, LB, and YPD agar medium (thickness is about 4 mm) to the plates and store at room temperature after cooling. 600 The corresponding semi-solid culture medium was melted in a microwave oven and dispensed into 10 mL EP tubes (about 7 mL per tube). After cooling to a suitable temperature, 0.1 mL of each pathogen was added, mixed well, poured into a plate, and spread evenly.

[0081] 3. After the agar surface is dry, use tweezers to gently place the sterile Oxford cup into the culture dish and take 0.1 mL of probiotic solution into the Oxford cup.

[0082] 4. Place the culture dish in a 4℃ refrigerator for diffusion overnight, and then transfer it to a 37℃ incubator. Observe the antibacterial effect and measure the size of the inhibition zone after 16 hours, and repeat 3 times for each group.

[0083] 1.6 Determination of enzyme production capacity of strains

[0084] Activate 5 strains of probiotics, take 5 μL of each and drop it on the skim milk powder culture medium, and culture it in a 37°C incubator for 48 hours. The skim milk powder culture medium is milky white. When the probiotics grow on the plate, the protease-producing strain can decompose the milk powder and produce a transparent circle around the colony. The higher the protease activity or the greater the yield produced by the strain, the larger the corresponding transparent circle will be. Therefore, by measuring the diameter of the transparent circle (D) and the diameter of the colony (d), the enzyme production ability of the strain can be judged according to the size of D / d, so as to screen out strains with stable protease production and high protease activity.

[0085] 1.7 Mutual inhibition test

[0086] 1. Preparation of double-layer plates: Add about 25 mL of MRS, LB, and YPD agar medium (thickness is about 4 mm) to each plate, cool it down and store it at room temperature. 600 The values ​​were adjusted to be consistent, the corresponding semi-solid culture medium was melted in a microwave oven and dispensed into 10mL EP tubes (about 7mL per tube). After cooling to the appropriate temperature, 0.1mL of each probiotic was added respectively, mixed well, poured into a plate and spread evenly.

[0087] 2. After the agar surface is dry, use tweezers to gently place the sterile Oxford cup into the culture dish, and take 0.1 mL of the corresponding probiotic solution into the Oxford cup.

[0088] 3. Place the culture dish in a 4℃ refrigerator for diffusion overnight, then transfer it to a 37℃ incubator. Observe the antibacterial effect after 16 hours, and repeat 3 times for each group.

[0089] 1.8 Animal experiments

[0090] The ambient temperature of the mice was 25℃, and the lighting time was strictly controlled, with 12h in the light and dark environment, and the mice were given free access to water and food. Forty seven-week-old SPF-grade male C57BL / 6 mice were randomly divided into four groups. There were 10 mice in each group, including the normal control group (Control group), the sodium dextran sulfate group (DSS group), the compound probiotics group (Probiotics group), and the sodium dextran sulfate + compound probiotics group (DSS+Probiotics group). After adapting to the breeding environment for 7 days, the compound probiotics treatment group was gavaged with 3×10 9 CFU compound probiotics (Bacillus licheniformis: Lactobacillus plantarum: Saccharomyces cerevisiae = 1:1:1) 0.2ml, the Control group and the DSS group were gavaged with the same amount of normal saline. All groups were given sterile drinking water for the first 14 days of the test period. On the 15th day of the test period, the Control group and the Probiotics group continued to be given sterile drinking water. The remaining treatment groups added 3% DSS to the sterile drinking water for 7 days. On the 24th day of the test period, the mice were killed and samples were taken. One part of the samples was fixed with 4% paraformaldehyde solution, and the other part was stored in a -80℃ refrigerator for testing.

[0091] Intestinal content samples were collected, placed in sterile centrifuge tubes, and stored in a -80°C refrigerator for subsequent experiments.

[0092] 2. Test results and analysis

[0093] 2.1 Cultivation and identification of probiotics

[0094] The colony morphology of probiotics is shown in the figure Figure 1As shown, the colonies of Bacillus subtilis and Bacillus licheniformis in LB solid medium are white, with a rough and opaque surface and irregular edges ( Figure 1 A, B). The colonies of Lactobacillus plantarum and Enterococcus faecalis in MRS solid medium are white with neat edges and raised ( Figure 1 C, D). The colonies of Saccharomyces cerevisiae on YPD solid medium are milky white and opaque, with neat edges and protrusions ( Figure 1 E). Gram staining results showed ( Figure 2 ), the four prokaryotic probiotics are all Gram-positive bacteria, appearing blue-purple under the microscope. Among them, Bacillus subtilis, Bacillus licheniformis and Lactobacillus plantarum are all short rods under the microscope, and Enterococcus faecalis appears spherical under the microscope.

[0095] Using the activated bacterial solution as a template, amplify the gene fragments of 16S rRNA and 26S rRNA (such as Figure 3 The PCR products were then sent to Jinkairui Biological Company for sequencing, and the sequences of each strain were compared by BLAST on the NCBI website. The results showed that all five strains were target strains.

[0096] 2.2 Determination of stress resistance and growth curve of probiotics

[0097] In the production and application of probiotic preparations, the ability of the strain to resist adverse environments has a decisive influence on the live bacteria content of the product. Figure 4 The results of the high temperature test show that ( Figure 4 A), each strain had good tolerance to high temperature, and the survival rate was over 50%, among which the survival rates of Enterococcus faecalis and Saccharomyces cerevisiae reached 81.53% and 82.51% respectively. The pH value and bile salt concentration of the culture medium were adjusted to simulate the environment of the host's digestive tract, and then the survival ability of probiotics in the host's digestive tract was tested. The results of the acid resistance test showed that ( Figure 4 B), the two strains of Bacillus had strong acid resistance, and the survival rates of Bacillus subtilis and Bacillus licheniformis reached 92.27% and 88.96% respectively. The results of the bile salt resistance test showed that ( Figure 4 C), Enterococcus faecalis and Saccharomyces cerevisiae had the best tolerance to bile salts, with survival rates reaching 66.9% and 69.88%, respectively.

[0098] The growth curve results showed that ( Figure 4 D), the five probiotic strains had high activity and could enter the logarithmic growth phase in a short time, among which Enterococcus faecalis had the fastest growth rate and reached the plateau phase at the 6th hour, while Lactobacillus plantarum and Saccharomyces cerevisiae entered the plateau phase at the 8th hour.

[0099] 2.3 Determination of antibacterial ability and enzyme production ability of probiotics

[0100] One of the mechanisms by which probiotics protect the host's intestinal health is the antagonism of pathogenic microorganisms. Therefore, it is necessary to test the inhibitory effect of probiotics on common intestinal pathogens such as Staphylococcus aureus and Escherichia coli in vitro. By comparing the inhibition zones produced by various probiotic strains, it was found that ( Figure 5 ), the antibacterial effects of the two lactic acid bacteria were more obvious, among which Lactobacillus plantarum had the best inhibitory effect on Staphylococcus aureus and Escherichia coli, and the diameter of the inhibition zone was the largest (Table 3).

[0101] Table 3 Antibacterial effect and enzyme production effect

[0102]

[0103] Note: Different lowercase letters in the same column indicate extremely significant differences (p<0.01).

[0104] The intestine is the place where animals digest and absorb nutrients, so the effect of probiotics on the digestion and absorption function of the host intestine is also an important indicator for evaluating its probiotic effect. Using milk powder as a special nutrient in the solid culture medium, the ratio of the diameter of the transparent circle produced by probiotics on the culture medium to the diameter of the colony can be used as an indicator to determine its protease production ability. The results of the protease production test showed that ( Figure 6 ), the transparent zone of the two Bacillus strains was the most obvious, followed by Saccharomyces cerevisiae. By comparison, it was found that Bacillus licheniformis had the best protease production ability, and the ratio of the transparent zone diameter to the colony diameter (D / d) was the largest, reaching 1.88 (Table 3).

[0105] 2.4 Detection of inhibitory effects between probiotics

[0106] In order to prevent the inhibitory effect between probiotics from affecting each other's growth and reproduction, and thus affecting the probiotic effect of probiotics in the host's intestine, it is necessary to test through the Oxford Cup test to ensure that there is no obvious mutual inhibition between the selected probiotics. After comparison of various previous tests, Bacillus licheniformis with the best protease production performance, Lactobacillus plantarum with the best inhibitory effect on common intestinal pathogens, and Saccharomyces cerevisiae with the best comprehensive stress resistance and a certain protease production ability were selected as potential strains of composite probiotics. One of the probiotics was spread on the solid culture medium, and the remaining probiotics were added to the Oxford Cup. The results showed that no obvious transparent circle appeared on the solid culture medium ( Figure 7 AC), proving that there is no obvious mutual inhibition between the probiotic strains and they can be used as composite probiotics.

[0107] 2.5 Compound probiotics improve DSS-induced colitis in mice

[0108] In order to explore the protective effect of compound probiotics on ulcerative colitis in mice, the body weight, food intake, disease activity index (DAI) and related organ indexes of mice in each treatment group were compared and analyzed. Figure 8 The results showed that the weight of mice began to decrease on the 5th day after DSS treatment ( Figure 8 A), and significantly lower than the Control group after 7 days. At the same time, the average feed intake of the DSS group after 7 days was significantly lower than that of the other three groups ( Figure 8 B). DAI combines the percentage of body weight loss, fecal viscosity and rectal bleeding to judge the severity of colitis in mice. The higher the score, the more severe the colitis. DAI after 5 days of DSS treatment was significantly higher than that of the Control group ( Figure 8 C), mice generally had diarrhea, sticky and foul-smelling feces, and some mice had blood in their stools. The relevant organ index refers to the ratio of organ weight to the weight of the mouse. When inflammation occurs, the organ will undergo edema, hyperplasia and other lesions, causing weight changes. Therefore, the relevant organ index can indicate the degree of individual inflammatory response to a certain extent. The results showed that the spleen and liver indexes of mice treated with DSS were significantly higher than those of the Control group ( Figure 8 D, E), indicating that the inflammation was more serious. The renal index of mice was also increased, but the difference was not significant ( Figure 8 F). The weight loss of mice was alleviated after the compound probiotic treatment. After 7 days, the weight of mice was significantly higher than that of the DSS group, and the DAI and related organ indexes were significantly lower than those of the DSS group. The above results show that compound probiotic treatment can alleviate the symptoms of ulcerative colitis in mice.

[0109] When the mice were dissected, the colon was completely removed, and the length was measured and photographed ( Fig. 9 A). Changes in colon length are one of the characteristic lesions of ulcerative colitis. Compared with normal individuals, the colon length of individuals with colitis is significantly shorter. The colon length of each group of mice was measured and analyzed ( Fig. 9 B), the colon of mice in the DSS group was significantly shorter than that in the Control group, and the colon of mice in the DSS+Probiotics group was significantly longer than that in the DSS group, indicating that the compound probiotics have a good protective effect on the colon of mice.

[0110] The colon sections of mice in each group were stained with HE, and the colon tissue morphology of each group was observed and compared under a microscope ( Fig.10 A), the colon mucosal tissue morphology of mice in the DSS group was severely lesioned, the colon mucosal layer was obviously degenerated and necrotic, the crypts were atrophied, and the base thickness increased. The tissue structure lesions in the DSS+Probiotics group were milder and still maintained the structural characteristics of the mucosal layer, which indicates that compound probiotics can effectively improve DSS-induced colon tissue damage.

[0111] The expression of intestinal tight junction proteins Claudin-1 and ZO-1 was further detected. Immunohistochemistry was performed on colon sections of mice in each group. The results showed that ( Fig.10 B, C), compared with the Control group, the positive signal of tight junction protein Claudin-1 was significantly weakened after DSS treatment, indicating that the protein expression of Claudin-1 was reduced and the intestinal barrier function was damaged. The positive signal after compound probiotic treatment was significantly enhanced compared with the DSS group. However, the positive signal of ZO-1 did not change significantly. The detection of Claudin-1 and ZO-1 mRNA levels in colon tissue also found that ( Fig.10 D, E), the mRNA levels of Claudin-1 and ZO-1 were significantly downregulated after DSS treatment, and the compound probiotic treatment could restore the mRNA levels of tight junction proteins. The above results suggest that compound probiotics can increase the expression of Claudin-1 and ZO-1 and restore intestinal barrier function.

[0112] 2.6 Effects of compound probiotics on intestinal oxidative damage in mice

[0113] Superoxide dismutase (SOD) is an important free radical scavenging enzyme in the body, which has an important influence on the balance of oxidation and anti-oxidation in the body. Glutathione (GSH) is a non-enzymatic antioxidant that can also scavenge free radicals in the body and protect other biological macromolecules. Malondialdehyde (MDA) is a peroxidation product generated by free radicals attacking lipids, which will affect the physiological effects of biological macromolecules such as proteins and can reflect the degree of oxidative damage to tissues. Lactate dehydrogenase (LDH) is stably present in the cytoplasm. When tissue cells are damaged and the cell membrane ruptures, LDH will be released to the extracellular space and enter the plasma. Therefore, changes in its enzyme activity in plasma can be used as a marker for detecting damage. Nrf2 is an important transcription factor that regulates oxidative stress and plays a regulatory role in the expression of antioxidant enzymes. HO-1 is an antioxidant factor regulated by it. Changes in the expression levels of Nrf2 and HO-1 can reflect the state of oxidative stress in the body. To explore whether the compound probiotics can improve intestinal oxidative damage, the T-SOD enzyme activity and GSH, MDA levels in the colon tissue and serum of mice, as well as the LDH enzyme activity in the serum ( Fig.11 AG). The results showed that after DSS treatment, T-SOD enzyme activity and GSH level were significantly reduced, while MDA level and LDH enzyme activity were significantly increased. At the same time, Western Blot results showed ( Fig.11HJ), the protein levels of Nrf2 and HO-1 in the colon tissue of mice decreased after DSS treatment. The above results indicate that the body suffered significant oxidative damage after DSS treatment. After the compound probiotics treatment, the T-SOD enzyme activity and GSH level increased significantly, the MDA level and LDH enzyme activity decreased significantly, and the protein levels of Nrf2 and HO-1 recovered, indicating that the compound probiotics have antioxidant function and can alleviate the oxidative damage caused by DSS to the intestine.

[0114] 2.7 Effects of compound probiotics on intestinal inflammatory response in mice

[0115] The NF-κB signaling pathway is an extremely important cell signaling pathway, which is involved in physiological responses such as inflammatory responses and immune regulation. In cells, NF-κB protein usually forms a dimer of p65 and p50, and is inactivated by binding to the inhibitory protein IκBα. When the pathway is activated, the IκBα protein detaches from the trimer and is hydrolyzed, and the p65 protein enters the nucleus to exert its effect. In order to explore the effects of compound probiotics on the NF-κB pathway in the intestine of mice, the expression levels of proteins related to the NF-κB pathway were detected. The test results showed that compared with the Control group, the protein expression level of p65 in the colon of mice treated with DSS was significantly increased, and the protein expression level of IκBα was significantly decreased, indicating that the NF-κB pathway was activated ( Fig.12 FH). At the same time, the mRNA levels of inflammatory factors IL-6, IL-1β, and TNF-α related to the NF-κB pathway increased significantly after DSS treatment compared with the Control group, while the mRNA level of the anti-inflammatory factor IL-10 decreased significantly ( Fig.12 AD). Myeloperoxidase (MPO) is an inflammatory marker. The MPO level in the DSS group was significantly increased compared with the Control group ( Fig.12 E). After the compound probiotic treatment, the levels of p65 protein, IL-6, IL-1β, TNF-α and MPO decreased compared with the DSS group, and the levels of IκBα protein and IL-10 were restored. These results indicate that the compound probiotic can exert anti-inflammatory function and reduce the inflammatory response of mice by inhibiting the activation of the NF-κB pathway.

[0116] 2.8 Effects of ulcerative colitis and compound probiotics on intestinal flora

[0117] 2.8.1 Effects of ulcerative colitis and compound probiotics on intestinal flora clustering

[0118] The effects of ulcerative colitis and compound probiotics on intestinal flora were evaluated by sequencing the intestinal flora of mouse colon contents. The rarefaction curve is composed of the number of sequencing and species abundance. When the curve tends to be flat, it indicates that the sampling depth is reasonable. At the same time, the species abundance of different samples can also be compared. The results show that the sampling depth of each group is reasonable ( Fig.13 A). The Shannon index curve is similar to the rarefaction curve, reflecting the relationship between microbial diversity and sequencing quantity. The larger the Shannon index, the higher the microbial diversity. The results show that the curves of each group tend to be flat ( Fig.13 B), the sampling is reasonable and can cover the information of most microorganisms in the sample. OUT cluster analysis was performed on each group ( Fig.13 C), the results showed that the number of characteristic OUTs in the Control group, DSS group, Probiotics group and DSS+Probiotics group were 1613, 861, 2415 and 1045, respectively. The Venn diagram can intuitively display the unique and common species among the groups. The unique OUT numbers of the four groups were 1114, 533, 1915 and 699, respectively, while the common OUT number was 152 ( Fig.13 D), the comparison showed that the OUT number in the DSS group was significantly lower than that in the Control group, and the OUT number increased after the compound probiotic treatment.

[0119] 2.8.2 Effects of ulcerative colitis and compound probiotics on intestinal flora diversity

[0120] The diversity of intestinal flora is usually analyzed in two dimensions: Alpha diversity and Beta diversity. Alpha diversity aims to describe the richness and species diversity of samples. We conducted statistical analysis on four Alpha diversity indices: ACE, Chao1, Shannon, and Simpson ( Fig.14 AD), from the results, the four different Alpha diversity indices all showed that the species diversity and abundance of the DSS group decreased compared with the Control group, and this trend was alleviated after the compound probiotic treatment. It is worth noting that the index of the Probiotics group increased compared with the Control group. Among the four indices, ACE, Chao1, and Shannon indexes showed significant differences (r<0.05), while the Simpson index had no significant difference.

[0121] Beta diversity indicates the differences in bacterial composition between different groups. Non-metric multidimensional scalar analysis (NMDS) and principal coordinate analysis (PCoA) based on the Weighted Unifrac algorithm can intuitively show the size of the differences between groups ( Fig.14E, F), the results show that the bacterial community structure of the DSS group and the Control group is obviously separated, while the bacterial community structure of the Control group and the Probiotics group is similar, and the bacterial community structure of the DSS group and the DSS+Probiotics group is similar. The distance heat map between samples is also drawn based on the Weighted Unifrac algorithm ( Fig.14 G), the difference between different samples can be intuitively seen. The transition from red to blue in the heat map indicates that the distance between samples is from far to near, that is, the difference between samples is from large to small. The UPGMA tree column diagram is composed of the abundance column diagram and the clustering tree. It can simultaneously display the microbial population composition of different samples and the clustering between samples. The shorter the distance between two samples, the closer their bacterial population composition is. The results show that the composition of samples in the same group is similar, the species composition of the DSS group and the Control group is the most different, and the DSS+Probiotics group is between the two ( Fig.14 H). These results indicate that DSS-induced ulcerative colitis can significantly change the intestinal flora composition of mice, which may be harmful to intestinal health, and this was improved after treatment with compound probiotics.

[0122] 2.8.3 Effects of ulcerative colitis and compound probiotics on intestinal flora composition

[0123] Further analysis of the composition of the intestinal flora at the phylum level ( Fig.15 ), the intestinal flora of mice in each treatment group was dominated by Firmicutes, Bacteroidetes, and Proteobacteria. After DSS treatment, the abundance of Proteobacteria and Campylobacter increased significantly, while the abundance of Bacteroidetes decreased significantly, and this trend was alleviated after the compound probiotic treatment. At the genus level ( Fig.16 ), the dominant flora in the Control group was mainly composed of unclassified_Muribaculaceae, Ileibacterium (Ileobacterium), and Prevotellaceae_UCG_001. After DSS treatment, the abundance of unclassified_Muribaculaceae, Ileibacterium (Ileobacterium), and Prevotellaceae_UCG_001 decreased significantly, and Escherichia_Shigella and Clostridium_sensu_stricto_1 became new dominant flora. After the compound probiotic treatment, the abundance of unclassified_Muribaculaceae, Ileibacterium (Ileobacterium), and Prevotellaceae_UCG_001 increased.

[0124] Linear discriminant analysis (LEfSe analysis) was performed on each group (LDA>4) to analyze the bacterial community that contributed most to the differences in bacterial community composition in each group ( Fig.17 A, B). The abundance of Akkermansia (Akermansia) of Verrucomicrobia and its sub-branches and Lactobacillus (Lactobacillus) of Firmicutes in the Control group was significantly different from that in other groups. The DSS group was composed of Helicobacter (Helicobacter), Plesiomonas (Plesiomonas), Enterobacterales (Enterobacterales) of Proteobacteria and Campylobacterales (Campylobacterales) of Campylobacter. In the Probiotics group, Prevotellaceae (Prevotellaceae) of Bacteroidetes, Lachnospiraceae_NK4A136_group, Clostridia_UCG_014, Oscillospiraceae (Oscillospiraceae) of Firmicutes were different from other groups. The species that were significantly different from other groups in the DSS+Probiotics group included Dubosiella, etc. These results show that both ulcerative colitis and compound probiotics can effectively change the composition of the intestinal flora of mice.

[0125] 2.8.4 Effects of ulcerative colitis and compound probiotics on the correlation and association of intestinal flora

[0126] The correlation network heat map can intuitively show the correlation between species. The spheres in the figure are representatives of species. The size of the spheres is proportional to the abundance of the species. The spheres are connected by lines to indicate that the two species are related. The thickness of the lines represents the strength of the correlation. Red and green represent positive and negative correlations, respectively. The results show ( Fig.18 AD), the microbial interactions among the four groups were significantly changed. After DSS treatment, the negative correlation ratio between microbiota increased, and the cooperative relationship between species weakened. However, compound probiotics could increase the positive correlation ratio between microbiota, that is, promote the cooperative relationship between species.

[0127] The heatmap is made of the correlation between species and environmental factors. The transition from red to blue in the heatmap indicates that the correlation between species and environmental factors transitions from positive correlation to negative correlation. The correlation coefficient between species and environmental factors is calculated by the Spearman algorithm, and intuitive correlation results can be obtained. The environmental factors related to antioxidant function and inflammation are statistically analyzed, and the results show that ( Fig.19A, B), unclassified_Muribaculaceae, Alistipes, Ileibacterium, Prevotellaceae_UCG_001, and unclassified_Lachnospiraceae were positively correlated with T-SOD enzyme activity, GSH, and Nrf2 levels, and negatively correlated with MDA levels and LDH enzyme activity; Clostridium_sensu_stricto_1, Escherichia_Shigella, and Parasutterella showed completely opposite correlations. On the other hand, Parasutterella, Clostridium_sensu_stricto_1, and Escherichia_Shigella were positively correlated with TNF-α, IL-1β, IL-6, p65, and MPO levels, and negatively correlated with IκBα and IL-10 levels; unclassified_Muribaculaceae, Prevotellaceae_UCG_001, unclassified_Lachnospiraceae, Alistipes, and Ileibacterium showed the opposite correlation.

[0128] 3.1 Screening of compound probiotics

[0129] When screening probiotics, stress resistance and probiotic properties are usually used as screening indicators. Stress resistance evaluates the ability of probiotics to survive in various harsh environments, in order to obtain probiotic products with high viable counts and ensure the activity of probiotics. Probiotic properties such as the antagonism and enzyme production ability of probiotics against pathogens evaluate the ability and mechanism of probiotics to protect the intestinal health of the host. Probiotics inhibit the growth and reproduction of common intestinal pathogens, protect the intestinal cells of the host from infection, and prevent the occurrence of diseases. The intestine is the main place for animals to digest and absorb nutrients, so the activity of digestive enzymes in the intestine plays an important role in maintaining normal intestinal function and protecting the health of the host. The enzyme production ability of probiotics can assist the host intestine in digestion and absorption, and provide certain support for the host's nutrient intake and metabolism. In our study, the three probiotic strains showed good performance in different screening indicators. Saccharomyces cerevisiae has excellent comprehensive stress resistance and can resist adverse living environments. The strain has good activity and also has a certain ability to produce proteases. Lactobacillus plantarum has the best inhibitory effect on Escherichia coli and Staphylococcus aureus, two common intestinal pathogens, suggesting that Lactobacillus plantarum may protect the host intestine by antagonizing pathogens and play an anti-infection role. The protease production ability of Bacillus licheniformis is the best among the five probiotics, suggesting that Bacillus licheniformis may improve the host's intestinal health by assisting the digestive function of the host's intestine. One of the advantages of compound probiotics over single probiotics is that different probiotics have different mechanisms of action to protect the host's health. The synergistic use of multiple probiotics may synergize different mechanisms of action to protect the host's health.

[0130] 3.2 Compound probiotics regulate NF-κB pathway to relieve intestinal inflammation in mice

[0131] Ulcerative colitis is a recurrent inflammatory bowel disease, the main symptoms of which are diarrhea and blood in the stool. Inflammation and oxidative stress are important factors in the occurrence and development of ulcerative colitis. NF-κB is a key transcription factor that regulates inflammation. It is also involved in the activation and production of various signaling pathways and signaling molecules in the body, and is involved in the regulation of many physiological activities in the body, such as inflammatory response, immune response, and cell growth. NF-κB is a dimer composed of p65 and p50. Under normal conditions, it forms a trimer with IκBα and is located in the cytoplasm. At this time, the NF-κB signaling pathway is in an inactive state, and IκBα exists as an inhibitory factor. When the upstream signal is transmitted here, IκB kinase is activated, prompting IκBα to be hydrolyzed, and then exposing the nuclear localization sequence. NF-κB enters the nucleus to regulate downstream genes, completing the activation of the NF-κB signaling pathway. NF-κB located in the nucleus can bind to newly synthesized inhibitory proteins and exit the nucleus to complete the cycle of activation and inactivation. The interaction between the NF-κB signaling pathway and inflammatory factors is also mutual. On the one hand, some inflammatory factors can act as upstream signals to regulate the NF-κB pathway. For example, IL-6 and TNF-α can activate the NF-κB pathway, thereby affecting the progression of inflammation in the body. On the other hand, when the NF-κB pathway is activated, it can also regulate the transcription of some inflammatory factors, causing their levels to rise, leading to inflammation and differentiation of immune cells. Therefore, when the regulation of the NF-κB pathway is out of control, the body may develop diseases such as inflammation, tumors, and autoimmune diseases. In previous studies, it was often found that there were signs of significant activation of the NF-κB signaling pathway in individuals with ulcerative colitis, and the levels of various related inflammatory factors were significantly increased. This was also verified in this study. In order to explore this point, we detected the levels of NF-κB pathway-related proteins and inflammatory factors in the colon tissues of each group of mice. After DSS treatment, the expression of p65 protein levels in the colon tissues of mice was significantly upregulated, and the level of inhibitory protein IκBα was significantly decreased, indicating that the NF-κB signaling pathway was significantly activated in individuals with colitis. At the same time, the mRNA levels of IL-6, IL-1β, and TNF-α were significantly increased, and the mRNA level of the anti-inflammatory factor IL-10 was significantly decreased. After the treatment of compound probiotics, these inflammatory activation trends were improved accordingly, that is, the compound probiotics inhibited the activation of the NF-κB signaling pathway and showed a good anti-inflammatory effect.

[0132] On the other hand, the NF-κB signaling pathway is also related to the expression of tight junction proteins in the intestinal barrier. When the pathway is blocked, the expression level of tight junction proteins will be upregulated, thereby restoring the damaged intestinal barrier and reducing diarrhea. Studies have shown that some cytokines such as TNF family members and IL-23 can regulate tight junction proteins. Tight junction proteins are one of the main components of the intestinal physical barrier and will largely affect the integrity of the intestinal mucosal barrier. In inflammatory bowel disease, the body's immune response will be abnormally activated, thereby changing the permeability of the intestinal mucosa and downregulating the expression of tight junction proteins. Similar results were found in our study. After DSS treatment, the expression of tight junction proteins Claudin-1 and ZO-1 in the mouse colon was significantly reduced, and this trend was reversed after treatment with compound probiotics, that is, compound probiotics can restore the expression level of intestinal tight junction proteins, repair the intestinal barrier, and thus improve the intestinal health of mice.

[0133] 3.3 Compound probiotics alleviate intestinal oxidative damage in mice caused by ulcerative colitis

[0134] In inflammatory bowel disease, excessive oxidative damage to body tissues can often be detected. This result is mainly attributed to the fact that upregulated inflammatory factors during inflammation can induce immune cells to produce reactive oxygen species. Excessive reactive oxygen species can also damage the body's normal tissues to a certain extent, ultimately damaging the immune system and causing more serious symptoms. The Nrf2 signaling pathway is a mechanism for the body to protect itself from oxidative damage. One of its mechanisms is to induce the body to produce antioxidant enzymes to remove peroxides in the body. When the body is oxidatively damaged, Nrf2 can enter the nucleus from the cytoplasm to regulate other downstream antioxidant genes to respond, thereby protecting tissues from damage. MDA is the final product of reactive oxygen attacking lipids. It can cause cross-linking of biological macromolecules such as nucleic acids and proteins, thereby affecting the normal physiological functions of these biological macromolecules. In many animal models of oxidative stress, MDA levels can be detected to be significantly upregulated. On the other hand, under conditions of oxidative stress, many common enzymes and non-enzymatic antioxidants are consumed by the body to remove excessive reactive oxygen species, so their content in the body will decrease significantly, such as SOD, GSH, etc. LDH is an enzyme widely present in tissues and organs. As an important protease in the body's energy metabolism, when tissues are damaged, LDH will be released into the blood, and the content in the blood will rise sharply. Therefore, LDH can be used as a marker of tissue damage. In our study, in order to measure the oxidative damage of each group of mice, we tested various indicators in the colon tissue and serum of mice and obtained similar results. After DSS-induced ulcerative colitis, it was found that LDH enzyme activity and MDA levels were significantly upregulated, while T-SOD enzyme activity and GSH levels decreased, and Nrf2 and HO-1 protein expression levels also decreased significantly, indicating that severe oxidative damage occurred in the intestines of mice. After treatment with compound probiotics, these trends of oxidative damage were significantly improved, that is, compound probiotics can alleviate oxidative damage in the intestines of mice.

[0135] 3.4 Supplementation of compound probiotics can regulate intestinal flora and improve ulcerative colitis

[0136] The rich diversity of intestinal microorganisms plays a vital role in maintaining the microecological balance in the intestine and the function of the intestinal mucosal barrier. The intestinal microecology is a complex and changeable ecosystem with a certain self-recovery ability. In the face of external interference, microbial communities with higher diversity often have better recovery ability to maintain the balance of the microecology. In previous studies, it was found that the composition of the intestinal flora of individuals with ulcerative colitis would be damaged to a certain extent, and harmful characteristics such as decreased species diversity and aggregation of harmful flora appeared, which is often related to the course of the disease. In our study, ulcerative colitis and compound probiotic treatment can change the diversity and composition structure of the intestinal flora. In DSS-induced ulcerative colitis mice, the composition of the intestinal flora changed significantly, and the abundance of Prevotellaceae_UCG_001 at the genus level decreased significantly. Prevotellaceae_UCG_001 can produce polysaccharide digestive enzymes, which are related to the production of short-chain fatty acids. At the same time, studies have found that Prevotellaceae_UCG_001 can alleviate lipid and glucose metabolic disorders and is a potential probiotic for improving intestinal function. In our correlation analysis, Prevotellaceae_UCG_001 showed a positive correlation with some antioxidant environmental factors such as SOD and GSH, and a negative correlation with some inflammatory factors such as IL-6 and TNF-α, which is consistent with previous studies. Under the protective effect of compound probiotics, the trend of decreased abundance of Prevotellaceae_UCG_001 was alleviated. In the results of linear discriminant analysis, the significantly different species in the DSS group included Helicobacter, Plesiomonas, Enterobacterales of the Proteobacteria phylum, and Campylobacterales of the Campylobacter phylum. Among them, Helicobacter is one of the common pathogens of the gastrointestinal tract and is associated with gastrointestinal diseases such as colitis and diarrhea (Gagnière et al 2016); Plesiomonas can survive in many mammals and is often associated with diseases such as diarrhea. For example, the model species Plesiomonas Shigelloides is an important intestinal pathogen that can cause food poisoning in animals and symptoms such as abdominal pain and diarrhea; Enterobacterales is a common pathogen of medical-associated infections that can endanger various systems of the body and even cause sepsis and endanger life in severe cases; Campylobacterales is widely present in various warm-blooded animals and, as a pathogen of zoonotic diseases, is one of the four major causes of diarrhea in the world.The significantly different species Dubosiella in the DSS+Probiotics group can participate in the metabolism of carbohydrates in the body to produce butyrate, providing an energy source for the host. At the same time, studies have found that its antioxidant function in elderly mice is better than resveratrol, so it has become one of the probiotics with anti-aging potential. In the Probiotics group, many beneficial bacteria are gathered. Prevotellacea (Prevotellaceae) is considered a probiotic associated with a plant-based diet, and studies have found that the reduction in the abundance of Prevotellacea (Prevotellaceae) is associated with certain diseases; Lachnospiraceae_NK4A136_group was found to be gathered in the intestines of mice that reduced obesity symptoms after improving their diet structure, and has the potential to improve intestinal homeostasis. At the same time, another study found that Lachnospiraceae_NK4A136_group showed a negative correlation with inflammatory factors and may have anti-inflammatory functions. In summary, both suffering from ulcerative colitis and supplementing with compound probiotics can significantly change the host's intestinal flora structure. Ulcerative colitis will cause more pathogens to accumulate in the intestines and reduce the abundance of many beneficial bacteria. Compound probiotics can improve this.

[0137] In summary, this study shows that the selected compound probiotics can resist the damage of ulcerative colitis by inhibiting the activation of the NF-κB signaling pathway, while reducing intestinal oxidative damage, repairing the intestinal barrier function, and restoring the structure of the intestinal flora to improve intestinal health. Therefore, the selected compound probiotics can be developed and utilized as feed additives to improve animal intestinal health.

[0138] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:

[0139] The composite probiotics of the present invention have excellent performance in stress resistance, antibacterial and enzyme production, etc.; they can improve the weight loss, increased disease activity index, intestinal barrier damage and intestinal flora imbalance of mice caused by ulcerative colitis; and they can reduce the inflammation and oxidative damage of ulcerative colitis in mice. The composite probiotics of the present invention can be used in the preparation of drugs for treating inflammatory bowel disease, and can also be used in the preparation of feed additives for improving the intestinal health of animals; they can be used in animal husbandry production, and by adding composite probiotics, production efficiency can be improved and intestinal damage can be alleviated, the effects caused by pathogenic microorganism infection, improper feeding and management, etc. can be improved, the intestinal barrier of animals can be reduced, the growth performance of animals can be improved, and serious economic losses caused by induced diseases can be avoided.

[0140] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A composite probiotic for improving inflammatory bowel disease, characterized in that: The invention comprises bacillus licheniformis, lactobacillus plantarum and saccharomyces cerevisiae; the usage ratio of the bacillus licheniformis, lactobacillus plantarum and saccharomyces cerevisiae is 1-3:1-3:1-3.

2. The composite probiotic according to claim 1, characterized in that: The usage ratio of the Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae is 1:1:

1.

3. The composite probiotic according to claim 1, characterized in that: The dosage of Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae is 1-3×10 9 CFU, 1-3×10 9 CFU, 1-3×10 9 CFU.

4. The composite probiotic according to claim 1, characterized in that: The dosage of Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae is 1×10 9 CFU, 1×10 9 CFU, 1×10 9 CFU.

5. The composite probiotic according to claim 1, characterized in that: The Bacillus licheniformis, Lactobacillus plantarum and Saccharomyces cerevisiae were all purchased from Shandong Weilan Biotechnology Co., Ltd. The product code of the Bacillus licheniformis is U-1000, the product code of the Lactobacillus plantarum is zw-1000, and the product code of the Saccharomyces cerevisiae is NJJM-200.

6. Use of the composite probiotic according to any one of claims 1 to 5 in the preparation of a medicament for treating inflammatory bowel disease.

7. Use of the composite probiotic according to claim 6 in the preparation of a medicament for treating inflammatory bowel disease, characterized in that: The inflammatory bowel disease is ulcerative colitis.

8. Use of the composite probiotic according to claim 7 in the preparation of a medicament for treating inflammatory bowel disease, characterized in that: The ulcerative colitis includes ulcerative colitis induced by dextran sulfate sodium.

9. Use of the composite probiotic according to any one of claims 1 to 5 in the preparation of a feed additive for improving the intestinal health of animals.

Citation Information

Cited By

  • Kombucha capable of improving ulcerative colitis as well as preparation method and application of kombucha

    CN120531034A